The FDA has signed off Phase 2 trial of FSD Pharma' (NASDAQ:HUGE) FSD201 (ultramicronized palmitoylethanolamide, or ultramicronized PEA) for the treatment of hospitalized COVID-19 patients. Patient dosing is expected to commence in October.
The 352-subject study will assess the efficacy and safety of FSD201 dosed at 600mg or 1200mg twice-daily, together with standard of care ((SoC)), with treatment period of 14 days.
The primary objective of the trial is to determine whether FSD201 plus SOC provides a significant improvement in the clinical status of patients (e.g., shorter time to symptom relief), at 28 days.
https://seekingalpha.com/news/3617534-fsd-pharma-on-go-mid-stage-covidminus-19-study-fsd201
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.